Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...

2026 PSMA & Beyond: Advancing Radioligand Therapy: Toxicity, Trial Design, and Emerging TargetsSent on 29 March 2026 2026 PSMA & Beyond: Emerging Targets and Trial Insights in Prostate CancerSent on ...

Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-Invasive Bladder Cancer (SURE-02): A Single-Arm, Phase 2 Study - Beyond the Abstract ...

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

Association Between Baseline Prostate MRI PI-RADS Classification and Risk of Gleason Upgrade During Active Surveillance: A Systematic Review and Meta-Analysis - Beyond the Abstract ...

Hashim Hashim joins Diane Newman for a conversation on the definitions of lower urinary tract dysfunction and the role and timing of urodynamics in the diagnosis of the specific condition. They also ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

ESMO 2025 final results of PRESTO (AFT-19), phase III trial of combined androgen blockade in patients with high-risk, biochemically relapsed prostate cancer.

Inherited Defects of piRNA Biogenesis Cause Transposon De-Repression, Impaired Spermatogenesis, and Human Male Infertility - Beyond the Abstract ...

(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a session on metastatic prostate cancer, and a presentation by Dr. Thomas Zilli discussing 24-month toxicity ...

New Masculinities in Uro-Oncology: A Social Theory That Contributes to the Mental Health of Patients with Penile Cancer - Beyond the Abstract ...